Vanguard Total International Bond Index Fund ETF vs Novavax Inc — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $47.81, while Novavax Inc trades at $7.94 (market cap $1.31B). The key difference: Novavax Inc is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BNDX | NVAX | |
|---|---|---|
52-Week High | $49.91 | $11.19 |
52-Week Low | $47.57 | $6.22 |
Market Cap | — | $1.31B |
Sector | — | Health |
Enterprise Value | — | $889.30M |
Signals from Pluang's Aura AI — not financial advice
BNDX trades at $47.835 with minimal daily movement (+0.09%), showing technical bearish signals from moving averages while oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payouts of $0.11-$0.12. Market sentiment reflects ongoing concerns about Treasury yields and inflation data, with institutional activity showing mixed positioning changes among major holders.
The international bond ETF faces headwinds from rising global yields and inflation pressures, though steady dividend income provides support. Key risks include Federal Reserve policy uncertainty and Middle East geopolitical tensions affecting oil prices. Institutional interest remains active with recent position adjustments, suggesting cautious but engaged professional investor sentiment.
Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.
The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.
Trailing returns across standard periods
The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →